argenx FIRST LOOK: 1Q25 results confirm CIDP momentum
argenx reported a strong quarter with Vyvgart sales coming in at $ 790m, in line with CSS, showcasing the robustness of the commercial engine. We note that the company again reached operating profitability for the quarter. Pipeline timelines are reiterated and we look ahead to the upcoming readout in seronegative gMG (2H25), as well as PoC results in lupus nephritis (Vyvgart, 4Q25), delayed graft function (empa, 2H25) and congenital myasthenic syndrome (‘119, 2H25). Accumulate/ € 670 TP reiterated.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.